Outcomes after early treatment with hydroxychloroquine and azithromycin: An analysis of a database of 30,423 COVID-19 patients.

ABSTRACT:

Background

Many studies have evaluated the use of hydroxychloroquine in COVID-19. Most retrospective observational studies demonstrate a benefit of using HCQ on mortality, but not most randomized clinical trials.

Methods

We analyzed raw data collected from a cohort of 30,423 patients with COVID-19 cared for at IHU Méditerranée Infection in Marseille France and extracted from the DRYAD open data platform. We performed univariate and multivariable logistic regressions with all-cause mortality within six weeks. Multivariable logistic regressions were adjusted for sex, age group (<50, 50-69, 70-89 and ​> ​89 years), periods (or variants), and type of patient management.

Results

Among 30,202 patients for whom information on treatment was available, 191/23,172 (0.82%) patie

SUBMITTER: Brouqui P 

PROVIDER: S-EPMC10651676 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature